Desmoid tumors are a rare subtype of soft tissue sarcomas that can cause pain, limited mobility and a decreased quality of life, the FDA said. Surgical removal has historically been used to treat these noncancerous tumors, but there is a high risk of it returning.
In a clinical trial of 142 adult patients, study participants received either 150 milligrams of Ogsiveo or a placebo twice a day. Progression-free survival was found in 41% of those taking Ogsiveo and 8% in the placebo group.
The FDA awarded the approval to SpringWorks Therapeutics.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
